Thapaliya Abhisek, Bhattarai Urza, Gautam Arun, Dhakal Deepak, Shah Bhupendra, Sharma Sanjib K
Department of Internal Medicine B.P Koirala Institute of Health Sciences Dharan Nepal.
Clin Case Rep. 2023 Jun 9;11(6):e7517. doi: 10.1002/ccr3.7517. eCollection 2023 Jun.
Intrapleural streptokinase can be an option for loculated hemorrhagic pleural effusion among patients receiving CAPD and under DAPT. Its use can be individualized based on risk benefit analysis by the treating clinician.
Pleural effusion is seen in up to 10 percent of patients on peritoneal dialysis (PD). A hemorrhagic pleural effusion is a diagnostic dilemma and a therapeutic challenge. We report a complicated case of 67 years old man with end stage renal disease, with coronary artery disease and stent in situ under dual antiplatelet therapy and continuous ambulatory peritoneal dialysis. The patient presented with left-sided loculated hemorrhagic pleural effusion. He was managed with intrapleural streptokinase therapy. His loculated effusion resolved without any local and systemic bleeding manifestations. Therefore, in poor resource settings, Intrapleural streptokinase can be an option for loculated hemorrhagic pleural effusion among patients receiving CAPD and under DAPT. Its use can be individualized based on risk benefit analysis by the treating clinician.
对于接受持续性非卧床腹膜透析(CAPD)且正在接受双联抗血小板治疗(DAPT)的患者,胸膜腔内注射链激酶可作为局限性出血性胸腔积液的一种治疗选择。治疗医生可根据风险效益分析进行个体化使用。
在接受腹膜透析(PD)的患者中,高达10%会出现胸腔积液。出血性胸腔积液是一个诊断难题和治疗挑战。我们报告了一例复杂病例,一名67岁的终末期肾病男性患者,患有冠状动脉疾病且冠状动脉内有支架,正在接受双联抗血小板治疗和持续性非卧床腹膜透析。该患者出现左侧局限性出血性胸腔积液。他接受了胸膜腔内链激酶治疗。其局限性胸腔积液消退,未出现任何局部和全身出血表现。因此,在资源匮乏地区,对于接受CAPD且正在接受DAPT的患者,胸膜腔内注射链激酶可作为局限性出血性胸腔积液的一种治疗选择。治疗医生可根据风险效益分析进行个体化使用。